IO Biotech, Inc.
$0.01
▼
-26.09%
2026-04-21 07:33:01
www.iobiotech.com
NMS: IOBT
Explore IO Biotech, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$0.55 M
Current Price
$0.01
52W High / Low
$2.79 / $0.01
Stock P/E
—
Book Value
$0.01
Dividend Yield
—
ROCE
-197.41%
ROE
-2.4%
Face Value
—
EPS
$-0.23
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
80
Beta
0.89
Debt / Equity
1,988.91
Current Ratio
2.01
Quick Ratio
3.33
Forward P/E
-0.13
Price / Sales
—
Enterprise Value
$-11.96 M
EV / EBITDA
0.13
EV / Revenue
—
Rating
Hold
Target Price
$2.18
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Tempest Therapeutics, Inc. | $1.94 | — | $27.83 M | — | -195.16% | -2.04% | $12.23 / $1.5 | $1.35 |
| 2. | Agios Pharmaceuticals, Inc. | $27.07 | — | $1.54 B | — | -38.86% | -30.2% | $46 / $22.24 | $20.41 |
| 3. | Impact BioMedical Inc. | $0.68 | — | $67.48 M | — | -26.29% | -1.04% | $1.95 / $0.36 | $0.12 |
| 4. | Vistagen Therapeutics, Inc. | $0.61 | — | $24.12 M | — | -78.03% | -1.02% | $5.14 / $0.43 | $1.28 |
| 5. | Compass Therapeutics, Inc. | $5.42 | — | $1.08 B | — | -35.42% | -41.29% | $6.88 / $1.6 | $1.1 |
| 6. | Palatin Technologies, Inc. | $22.07 | — | $39.22 M | — | 478.76% | -3.79% | $31 / $2 | $6.53 |
| 7. | Adial Pharmaceuticals, Inc. | $1.63 | — | $2.33 M | — | -147.82% | -1.71% | $687.5 / $1.54 | $4.75 |
Quarterly Results
Figures shown in M / B
| Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -19.36 M | -23.17 M | -22.58 M | -26.94 M | -26.5 M |
| Net Profit | -8.38 M | -26.22 M | -22.42 M | -31.33 M | -24.02 M |
| EPS in Rs | -0.12 | -0.36 | -0.31 | -0.44 | -0.33 |
Profit & Loss
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -95.18 M | -91.44 M | -71.42 M | -41.23 M |
| Net Profit | -95.49 M | -86.08 M | -71.46 M | -67.88 M |
| EPS in Rs | -1.33 | -1.2 | -0.99 | -0.94 |
Balance Sheet
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Total Assets | 67.7 M | 150.72 M | 151.81 M | 222.29 M |
| Total Liabilities | 20.68 M | 17.56 M | 12.95 M | 10.36 M |
| Equity | 47.02 M | 133.16 M | 138.85 M | 211.92 M |
| Current Assets | 64.95 M | 147.25 M | 148.22 M | 221.74 M |
| Current Liabilities | 19.49 M | 15.72 M | 10.68 M | 10.3 M |
Cash Flow
Last available yearly cash flow history
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Operating CF | -82.35 M | -71.74 M | -59.73 M | -40.65 M |
| Investing CF | -0.04 M | -0.32 M | -0.69 M | -0.15 M |
| Financing CF | 0 M | 71.86 M | 0 M | 252.95 M |
| Free CF | -82.39 M | -72.06 M | -60.42 M | -40.8 M |
| Capex | -0.04 M | -0.32 M | -0.69 M | -0.15 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -10.93% | -20.47% | -5.27% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.